Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM)
Industry: Healthcare

Oasmia Pharmaceutical AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company's approved products include Paclical/Apealea for the treatment of ovarian and metastatic breast cancer; and Doxophos for the treatment of various doxorubicin indications. It also develops Docecal for breast cancer; OAS-19 and KB9520 for various cancers; Paccal Vet for mammary carcinoma and squamous cell carcinoma; and Doxophos Vet for lymphoma. Oasmia Pharmaceutical AB was founded in 1988 and is based in Uppsala, Sweden.

Current Quote*
Last: $1.560
Change: -0.010
Book: $2.545
Volume: 7,294

As Of: 08/21 13:25 ET
*Quotes delayed by 20min.

Graphs for OASM

3 Month Graph

6 Month Graph

1 Year Graph